Woodmont Investment Counsel’s AbbVie ABBV Stock Holding History

Woodmont Investment Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.72M	Sell	22,718 -383	-2%	-$82.4K	0.31%	64
2026 Q1	$5.02M	Sell	23,101 -149	-0.6%	-$33.1K	0.31%	61
2025 Q4	$5.31M	Sell	23,250 -115	-0.5%	-$26.2K	0.33%	59
2025 Q3	$5.41M	Buy	23,365 +65	+0.3%	+$13.2K	0.36%	56
2025 Q2	$4.32M	Buy	23,300 +37	+0.2%	+$6.88K	0.29%	65
2025 Q1	$4.87M	Sell	23,263 -200	-0.9%	-$38.9K	0.35%	62
2024 Q4	$4.17M	Sell	23,463 -1,505	-6%	-$277K	0.31%	64
2024 Q3	$4.93M	Sell	24,968 -650	-3%	-$121K	0.37%	56
2024 Q2	$4.39M	Sell	25,618 -140	-0.5%	-$23.2K	0.36%	57
2024 Q1	$4.69M	Sell	25,758 -235	-0.9%	-$40.5K	0.4%	53
2023 Q4	$4.03M	Sell	25,993 -910	-3%	-$133K	0.38%	56
2023 Q3	$4.01M	Sell	26,903 -518	-2%	-$76K	0.42%	56
2023 Q2	$3.69M	Sell	27,421 -672	-2%	-$98.5K	0.38%	60
2023 Q1	$4.48M	Buy	28,093 +1,031	+4%	+$158K	0.48%	53
2022 Q4	$4.37M	Buy	27,062 +86	+0.3%	+$13.2K	0.5%	54
2022 Q3	$3.62M	Buy	26,976 +1,202	+5%	+$172K	0.45%	59
2022 Q2	$3.95M	Buy	25,774 +678	+3%	+$104K	0.49%	56
2022 Q1	$4.07M	Buy	25,096 +900	+4%	+$131K	0.47%	60
2021 Q4	$3.28M	Sell	24,196 -189	-0.8%	-$22.3K	0.42%	60
2021 Q3	$2.63M	Sell	24,385 -109	-0.4%	-$12.5K	0.38%	65
2021 Q2	$2.76M	Buy	24,494 +1,722	+8%	+$194K	0.43%	58
2021 Q1	$2.46M	Buy	22,772 +1,499	+7%	+$160K	0.42%	58
2020 Q4	$2.28M	Buy	21,273 +2,650	+14%	+$255K	0.43%	59
2020 Q3	$1.63M	Buy	18,623 +895	+5%	+$84.3K	0.35%	70
2020 Q2	$1.74M	Sell	17,728 -875	-5%	-$77K	0.42%	62
2020 Q1	$1.42M	Sell	18,603 -2,461	-12%	-$210K	0.39%	69
2019 Q4	$1.86M	Sell	21,064 -200	-0.9%	-$16.6K	0.42%	62
2019 Q3	$1.61M	Sell	21,264 -562	-3%	-$38.5K	0.39%	69
2019 Q2	$1.59M	Sell	21,826 -675	-3%	-$53.1K	0.39%	68
2019 Q1	$1.81M	Sell	22,501 -1,197	-5%	-$97.9K	0.47%	60
2018 Q4	$2.19M	Sell	23,698 -199	-0.8%	-$17.5K	0.62%	51
2018 Q3	$2.26M	Sell	23,897 -969	-4%	-$91.9K	0.62%	49
2018 Q2	$2.3M	Buy	24,866 +39	+0.2%	+$3.81K	0.64%	44
2018 Q1	$2.35M	Sell	24,827 -3,542	-12%	-$389K	0.65%	46
2017 Q4	$2.74M	Sell	28,369 -1,225	-4%	-$115K	0.71%	44
2017 Q3	$2.63M	Sell	29,594 -2,760	-9%	-$210K	0.72%	43
2017 Q2	$2.35M	Sell	32,354 -7,889	-20%	-$530K	0.66%	48
2017 Q1	$2.52M	Hold	40,243	–	–	0.73%	45
2016 Q4	$2.52M	Sell	40,243 -480	-1%	-$29.3K	0.72%	43
2016 Q3	$2.57M	Sell	40,723 -1,399	-3%	-$90.6K	0.74%	40
2016 Q2	$2.61M	Sell	42,122 -3,070	-7%	-$187K	0.78%	40
2016 Q1	$2.58M	Sell	45,192 -3,305	-7%	-$184K	0.78%	37
2015 Q4	$2.87M	Buy	48,497 +180	+0.4%	+$10.4K	0.85%	35
2015 Q3	$2.63M	Sell	48,317 -2,860	-6%	-$186K	0.8%	36
2015 Q2	$3.44M	Sell	51,177 -4,815	-9%	-$314K	1%	26
2015 Q1	$3.28M	Buy	55,992 +2,334	+4%	+$141K	1.01%	29
2014 Q4	$3.51M	Sell	53,658 -2,634	-5%	-$166K	1.08%	28
2014 Q3	$3.25M	Sell	56,292 -9,851	-15%	-$547K	0.93%	31
2014 Q2	$3.73M	Buy	66,143 +6,075	+10%	+$319K	1.05%	25
2014 Q1	$3.09M	Sell	60,068 -408	-0.7%	-$20.6K	0.9%	31
2013 Q4	$3.19M	Sell	60,476 -2,915	-5%	-$143K	0.96%	30
2013 Q3	$2.83M	Buy	63,391 +65	+0.1%	+$2.88K	1.03%	28
2013 Q2	$2.62M	Buy	+63,326	New	+$2.77M	0.87%	35

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Woodmont Investment Counsel's ABBV Position: Q2 2026 in Review

Woodmont Investment Counsel reduced its AbbVie (ABBV) stake by 1.7% in Q2 2026, selling an estimated $82.4K and leaving 22,718 shares worth $5.72M. The position accounts for 0.31% of the portfolio, ranked #64.

Woodmont Investment Counsel first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Woodmont Investment Counsel held 22,718 shares of AbbVie worth $5.72M as of Q2 2026.
Woodmont Investment Counsel sold 383 AbbVie shares in Q2 2026, an estimated $82.4K.
AbbVie made up 0.31% of Woodmont Investment Counsel's portfolio in Q2 2026, its #64 holding.
Woodmont Investment Counsel first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Woodmont Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.